Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

Imatinib (STI571 or CGP57148B) is an innovative treatment for tumours with a constitutively activated form of c-ABL, c-KIT, or PDGFR. Such tumours include Philadelphia-chromosome-positive (Ph-positive) leukaemias, gastrointestinal stromal tumours, and PDGFR-positive leukaemias. Diseases such as primary hypereosinophilia and dermatofibrosarcoma protuberans also seem to respond to imatinib. Clinical trials assessing the therapeutic effects of imatinib have shown that the drug is highly effective with few associated side-effects, achieving durable cytogenetic responses in many patients with chronic-phase BCR-ABL-positive leukaemias. However, the emergence of resistance, particularly in patients with acute leukaemias, has prompted intense research, and many are concerned about the future prospects for imatinib. The resistance has been found in patients with acute-phase disease, but may also occur in patients with chronic-phase disease. Two cellular mechanisms for resistance to imatinib have been identified: amplification of BCR-ABL gene and mutations in the catalytic domain of the protein. In addition, suboptimum inhibition of BCR-ABL in vivo could contribute to the selection of resistant cells. We have summarised all currently available data on resistance to imatinib, both published and unpublished, including the mechanisms of resistance identified so far, and their clinical relevance to the different forms of Ph-positive leukaemias is discussed. Furthermore, we discuss strategies to overcome or prevent the development of resistance.

[1]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[2]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[3]  B. Druker,et al.  Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Hubbard.  Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog , 1997, The EMBO journal.

[5]  M. Zucchetti,et al.  Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. , 2002, Blood cells, molecules & diseases.

[6]  C. Barthe,et al.  Roots of clinical resistance to STI-571 cancer therapy. , 2001, Science.

[7]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[8]  C. Gambacorti-Passerini,et al.  Decrease of resistance to imatinib in leukaemia [3] (multiple letters) , 2002 .

[9]  N. Lydon,et al.  Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. , 1997, Blood cells, molecules & diseases.

[10]  J. Griffin,et al.  Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. , 2000, Blood.

[11]  M. Zucchetti,et al.  α1 Acid Glycoprotein Binds to Imatinib (STI571) and Substantially Alters Its Pharmacokinetics in Chronic Myeloid Leukemia Patients , 2003 .

[12]  J. Melo,et al.  The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.

[13]  G. Superti-Furga,et al.  Autoinhibition of c-Abl , 2002, Cell.

[14]  M. K. Magnússon,et al.  Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. , 2002, Blood.

[15]  David Elashoff,et al.  Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study , 2002, The Lancet.

[16]  M. Schwarz,et al.  Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. , 2002, Blood cells, molecules & diseases.

[17]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[18]  Susan M. Watanabe,et al.  An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity , 1984, Cell.

[19]  Decrease of resistance to imatinib in leukaemia , 2002, The Lancet.

[20]  J. Griffin.  Resistance to targeted therapy in leukaemia , 2002, The Lancet.

[21]  Jürg Zimmermann,et al.  Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives , 1997 .

[22]  J. Eary,et al.  Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Griffin,et al.  ARG tyrosine kinase activity is inhibited by STI571. , 2001, Blood.

[24]  C. Antonescu,et al.  Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans , 2002, International journal of cancer.

[25]  Claude Preudhomme,et al.  Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. , 2002, Blood.

[26]  R. Herrmann,et al.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.

[27]  J. Melo,et al.  Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. , 2000, Hematology. American Society of Hematology. Education Program.

[28]  B. Druker,et al.  Chronic myeloid leukemia: current treatment options. , 2001, Blood.

[29]  Martin C. Müller,et al.  Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy , 2001 .

[30]  C. Sawyers.  Research on Resistance to Cancer Drug Gleevec , 2001, Science.

[31]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[32]  S. de Vos,et al.  Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. , 2002, Blood.

[33]  J. Melo,et al.  Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.

[34]  M. Varella‐Garcia,et al.  Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. , 2000, Blood.

[35]  B. Bain,et al.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. , 2002, The New England journal of medicine.

[36]  M. Baccarani,et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.

[37]  C. Peschel,et al.  BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study , 2002, The Lancet.

[38]  J. Melo,et al.  Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. , 2001, Blood.

[39]  A. Tefferi,et al.  Treatment of hypereosinophilic syndrome with imatinib mesilate , 2002, The Lancet.

[40]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.

[41]  R. Larson,et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.

[42]  B. Druker,et al.  Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571* , 2002, The Journal of Biological Chemistry.

[43]  M. Zucchetti,et al.  Role of (cid:1) 1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL + Leukemic Cells to the Abl Inhibitor STI571 , 2000 .

[44]  Schaller Jl,et al.  Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. , 2001 .

[45]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[46]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[47]  B. Druker,et al.  STI571: a paradigm of new agents for cancer therapeutics. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  E. Buchdunger,et al.  In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. , 1999, Journal of the National Cancer Institute.

[49]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[50]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[51]  Sante Tura,et al.  A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.

[52]  J. Klein,et al.  The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. , 2001, Blood.

[53]  S. Hubbard,et al.  Crystallographic and Solution Studies of an Activation Loop Mutant of the Insulin Receptor Tyrosine Kinase , 2001, The Journal of Biological Chemistry.

[54]  G. Schulz,et al.  Adenylate kinase motions during catalysis: an energetic counterweight balancing substrate binding. , 1996, Structure.

[55]  S. Hubbard,et al.  Mechanism-based design of a protein kinase inhibitor , 2001, Nature Structural Biology.